Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Tuesday, Benzinga reports. Royal Bank of Canada currently has a $1,260.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on REGN. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Wells Fargo & Company restated an “overweight” rating and set a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 23rd. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ REGN opened at $928.90 on Tuesday. Regeneron Pharmaceuticals has a 12-month low of $769.19 and a 12-month high of $1,211.20. The firm’s 50-day simple moving average is $1,098.29 and its 200 day simple moving average is $1,040.67. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The company has a market cap of $102.40 billion, a price-to-earnings ratio of 24.60, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business earned $8.79 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals will post 37.66 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Orrstown Financial Services Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $237,000. Nisa Investment Advisors LLC lifted its position in Regeneron Pharmaceuticals by 33.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 29,742 shares of the biopharmaceutical company’s stock worth $31,266,000 after buying an additional 7,506 shares in the last quarter. Concord Wealth Partners boosted its stake in shares of Regeneron Pharmaceuticals by 9.9% during the 3rd quarter. Concord Wealth Partners now owns 989 shares of the biopharmaceutical company’s stock worth $1,040,000 after buying an additional 89 shares during the last quarter. Welch Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 3rd quarter. Welch Group LLC now owns 360 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 150 shares in the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its position in shares of Regeneron Pharmaceuticals by 8.6% in the third quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 1,829 shares of the biopharmaceutical company’s stock valued at $1,923,000 after acquiring an additional 145 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.